Peregrine Pharmaceuticals Inc - Rebound??
Seite 1 von 3 Neuester Beitrag: 25.04.21 01:16 | ||||
Eröffnet am: | 24.09.12 17:23 | von: Vzt83 | Anzahl Beiträge: | 55 |
Neuester Beitrag: | 25.04.21 01:16 | von: Klaudiayohsa | Leser gesamt: | 17.273 |
Forum: | Hot-Stocks | Leser heute: | 4 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 > |
Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015
TUSTIN, Calif., March 5, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced that it will report financial results for the third quarter fiscal year (FY) 2015 ended January 31, 2015 on March 12, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the third quarter ended January 31, 2015 of FY 2015 and will review recent progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
http://seekingalpha.com/news/...pharma-ups-revenues-46-percent-in-fq3
Peregrine Pharma ups Erlöse 46% in FQ3
13. März 2015, 07.26 Uhr ET | Über: Peregrine Pharmaceuticals ... (PPHM) | By: Mamta Mayani , SA Nachrichtenredakteur
Peregrine Pharmaceuticals ( PPHM + 1,4%)
FQ3 Ergebnisse : Umsatz: $ 5,7 Mio. (+ 46,2%);
COGS: $ 3,1 Mio. (+ 29,2%);
F & E-Kosten: $ 11,3 Mio. (+ 71,2%);
SG & A: $ 4,3 Mio. (-6,5%); Betriebsverlust: ($ 13M) (-34,0%);
Nettoverlust: ($ 14M) (-44,3%);
Das Ergebnis je Aktie: ($ 0,08) (-33,3%); Schnell Vermögen: $ 55,2 Mio. (-28,8%).
Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=957281
So lange hier Nichts klar definiert wird zählt die Substanz und die liegt so ca. bei 0,8 je Aktie.... 0 ganz bestimmt nicht....
läuft die nach 2-3 Tagen Depression mal richtig an, sind schnelle 50-70% drin und dann Tschüß auf zur nächsten und vergessen. ;-)
"This is an exciting milestone for our biomanufacturing business, which already had 20% revenue growth in our last fiscal year to $26.7 million and is expected to grow to $35-40 million in revenue for the current fiscal year that ends April 30. "
Mehr:
March 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the companys prior manufacturing capacity, supporting up to an additional $40 million in revenue each year.
This is an exciting milestone for our biomanufacturing business, which already had 20% revenue growth in our last fiscal year to $26.7 million and is expected to grow to $35-40 million in revenue for the current fiscal year that ends April 30. The newly commissioned biomanufacturing suite is a state-of-the-art facility that utilizes fully disposable manufacturing systems at up to the 2,000-liter manufacturing scale. These unique capabilities provide flexibility that can meet the needs of our diverse clients, with the potential to generate an additional $40 million in revenue, said Steven W. King, president and chief executive officer of Peregrine. We have already had a tremendous response to the new facility and look forward to continuing to grow our biomanufacturing business which is an integral part of our overall business strategy.
Peregrines new 40,000 square foot biomanufacturing facility is designed to utilize the most cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process for late Phase III clinical and commercial production of biologics. The facility is located adjacent to the companys current campus in Orange County, California.
http://www.4-traders.com/PERE-PHARP-15856502/news/...anufac-21971939/
Bei Peregrine könnte es m.E. heute nochmal einen schönen Hüpfer nach oben geben.
Gestern schloss der Kurs bei $0.4906. Nachbörslich ging es gestern noch hoch auf 0,55 Dollar. Bedeutet nicht viel, gewiss, aber der Trend nach dem heftigen Kursrutsch zeigt wieder ein wenig nach oben. Die o.g. News sickerte gestern langsam durch und heute dürften da noch ein paar Nachwehen kommen.
Morgen vor Börsenstart kommen Zahlen. Die Aktie könnte morgen richtig durchstarten,
oder aber auch runterrauschen.
Das Teil ist ein heißer Zock. Da bin ich dabei , dat is prihima.
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
- Drug Development Strategy to Focus on Early Stage Clinical Trials of Bavituximab and Immuno-Oncology (I-O) Combinations -
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=973959